Product Description: Gadoxetate (Gd-EOB-DTPA) Disodium is a contrast agent in magnetic resonance imaging (MRI) of the hepatobiliary system, which accumulates in normal, functioning hepatocytes. Gadoxetate Disodium aggravates liver fibrosis (LF) induced gadolinium deposition in the liver and deep cerebellar nuclei (DCN) of rats without significant acute histological alterations. Gadoxetate Disodium is used to evaluate focal liver lesions, such as hepatocellular carcinoma or dysplastic nodules[1][2][3][4][5][6].
Applications: Neuroscience-Neuromodulation
Formula: C23H28GdN3Na2O11
References: [1]Schuhmann-Giampieri G, et al. Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology. 1992 Apr;183(1):59-64./[2]Katsube T, et al. Estimation of liver function using T1 mapping on Gd-EOB-DTPA-enhanced magnetic resonance imaging. Invest Radiol. 2011 Apr;46(4):277-83./[3]Saito K, et al. Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase. Magn Reson Med Sci. 2005;4(1):1-9./[4]Chernyak V, et al. Use of gadoxetate disodium in patients with chronic liver disease and its implications for liver imaging reporting and data system (LI-RADS)[J]. J Magn Reson Imaging. 2019 May;49(5):1236-1252. /[5]Huh J, et al. Troubleshooting Arterial-Phase MR Images of Gadoxetate Disodium-Enhanced Liver[J]. Korean J Radiol. 2015 Nov-Dec;16(6):1207-15./[6]Wei P, et al. Gadolinium deposition in the liver and brain in a rat model with liver fibrosis after intravenous administration of gadoxetate disodium[J]. Heliyon. 2024 Mar 8;10(6):e27419.
CAS Number: 135326-22-6
Molecular Weight: 725.71
Compound Purity: 99.0
Research Area: Cancer
Solubility: DMSO : 24 mg/mL (ultrasonic)/H2O : ≥ 100 mg/mL
Target: Biochemical Assay Reagents
English
Deutsch
